The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia

被引:0
|
作者
Masamitsu Yanada
Shingo Yano
Yachiyo Kuwatsuka
Koji Kawamura
Takahiro Fukuda
Tatsuo Ichinohe
Yoshiko Hashii
Hideki Goto
Koji Kato
Fumihiko Ishimaru
Atsushi Sato
Makoto Onizuka
Keitaro Matsuo
Yuri Ito
Atsumi Yanagisawa
Marie Ohbiki
Ken Tabuchi
Yoshiko Atsuta
Junya Kanda
Takaaki Konuma
机构
[1] Nagoya City University East Medical Center,Research Institute for Radiation Biology and Medicine
[2] Aichi Cancer Center,Graduate School of Medicine
[3] The Jikei University School of Medicine,The Institute of Medical Science
[4] Nagoya University Hospital,undefined
[5] Tottori University Hospital,undefined
[6] National Cancer Center Hospital,undefined
[7] Hiroshima University,undefined
[8] Osaka International Cancer Institute,undefined
[9] Hokkaido University Hospital,undefined
[10] Kyushu University Hospital,undefined
[11] Japanese Red Cross Kanto-Koshinetsu Block Blood Center,undefined
[12] Miyagi Children’s Hospital,undefined
[13] Tokai University School of Medicine,undefined
[14] Aichi Cancer Center Research Institute,undefined
[15] Osaka Medical and Pharmaceutical University,undefined
[16] Japanese Data Center for Hematopoietic Cell Transplantation,undefined
[17] Aichi Medical University,undefined
[18] Kyoto University,undefined
[19] The University of Tokyo,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
This study aimed to address the prognostic impact of center experience based on the data of 7821 adults with acute myeloid leukemia who underwent allogeneic hematopoietic cell transplantation (HCT) from 2010 to 2019 in Japan, where medical care was provided within a uniform healthcare system. Center experience was defined based on the number of allogeneic HCTs performed for any indication during the study period, by which centers were divided into low-, intermediate-, and high-volume centers. After adjusting for known confounding factors, the risk of overall mortality was lowest for the high-volume centers and highest for the low-volume centers, with the difference between the center categories attributed primarily to the risk of relapse. Patients transplanted at high-volume centers had higher risks of acute and chronic graft-versus-host diseases but without an increased risk of non-relapse mortality (NRM). These findings reveal the presence of a center effect in allogeneic HCT conducted during the past decade in Japan, highlighting the difference in relapse based on center experience. The weaker effect on NRM compared with that on relapse suggests that the transplantation care quality is becoming equalized across the country.
引用
收藏
页码:541 / 549
页数:8
相关论文
共 50 条
  • [21] Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia: Similar Outcomes Regardless of Donor Type
    Warlick, Erica D.
    de Latour, Regis Peffault
    Shanley, Ryan
    Robin, Marie
    Bejanyan, Nelli
    Xhaard, Alienor
    Brunstein, Claudio
    de Fontbrune, Flore Sicre
    Ustun, Celalettin
    Weisdorf, Daniel J.
    Socie, Gerard
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : 357 - 363
  • [22] ACUTE MYELOID LEUKEMIA AND ALLOGENEIC TRANSPLANTATION: SINGLE-CENTER EXPERIENCE
    Colmenares, Rafael
    Martinez-Sanchez, Pilar
    Maria Sanchez-Pina, Jose
    Corona, Magdalena
    Saez, Adolfo J.
    Gil-Alos, Daniel
    Gil-Manso, Rodrigo
    Calbacho, Maria
    Martinez-Lopez, Joaquin
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 175 - 175
  • [23] OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN THIRD REMISSION
    Beitinjaneh, A.
    Jakob, J.
    Saliba, R.
    Chen, J.
    Rondon, G.
    Giralt, S.
    Cortes, J. E.
    Champlin, R.
    De Lima, M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S328 - S328
  • [24] Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes
    Yanada, Masamitsu
    Konuma, Takaaki
    Yamasaki, Satoshi
    Kondo, Tadakazu
    Fukuda, Takahiro
    Shingai, Naoki
    Sawa, Masashi
    Ozawa, Yukiyasu
    Tanaka, Masatsugu
    Uchida, Naoyuki
    Nakamae, Hirohisa
    Katayama, Yuta
    Matsuoka, Ken-ichi
    Kimura, Takafumi
    Kanda, Yoshinobu
    Ichinohe, Tatsuo
    Atsuta, Yoshiko
    Yano, Shingo
    BONE MARROW TRANSPLANTATION, 2021, 56 (05) : 1126 - 1133
  • [25] Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes
    Masamitsu Yanada
    Takaaki Konuma
    Satoshi Yamasaki
    Tadakazu Kondo
    Takahiro Fukuda
    Naoki Shingai
    Masashi Sawa
    Yukiyasu Ozawa
    Masatsugu Tanaka
    Naoyuki Uchida
    Hirohisa Nakamae
    Yuta Katayama
    Ken-ichi Matsuoka
    Takafumi Kimura
    Yoshinobu Kanda
    Tatsuo Ichinohe
    Yoshiko Atsuta
    Shingo Yano
    Bone Marrow Transplantation, 2021, 56 : 1126 - 1133
  • [26] Recent advances in allogeneic hematopoietic cell transplantation for acute myeloid leukemia
    Gomez-Arteaga, Alexandra
    Gyurkocza, Boglarka
    CURRENT OPINION IN HEMATOLOGY, 2020, 27 (02) : 115 - 121
  • [27] Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia
    Lipof, Jodi J.
    Loh, Kah Poh
    O'Dwyer, Kristen
    Liesveld, Jane L.
    CANCERS, 2018, 10 (06)
  • [28] Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission
    Yanada, Masamitsu
    Yamasaki, Satoshi
    Kondo, Tadakazu
    Kawata, Takahito
    Harada, Kaito
    Uchida, Naoyuki
    Doki, Noriko
    Yoshihara, Satoshi
    Katayama, Yuta
    Eto, Tetsuya
    Tanaka, Masatsugu
    Takada, Satoru
    Kawakita, Toshiro
    Nishida, Tetsuya
    Ota, Shuichi
    Serizawa, Kentaro
    Onizuka, Makoto
    Kanda, Yoshinobu
    Fukuda, Takahiro
    Atsuta, Yoshiko
    Konuma, Takaaki
    LEUKEMIA, 2024, 38 (03) : 513 - 520
  • [29] Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia
    Gyurkocza, Boglarka
    Storb, Rainer
    Storer, Barry E.
    Chauncey, Thomas R.
    Lange, Thoralf
    Shizuru, Judith A.
    Langston, Amelia A.
    Pulsipher, Michael A.
    Bredeson, Christopher N.
    Maziarz, Richard T.
    Bruno, Benedetto
    Petersen, Finn B.
    Maris, Michael B.
    Agura, Edward
    Yeager, Andrew
    Bethge, Wolfgang
    Sahebi, Firoozeh
    Appelbaum, Frederick R.
    Maloney, David G.
    Sandmaier, Brenda M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (17) : 2859 - 2867
  • [30] Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
    Kanakry, Christopher G.
    de Lima, Marcos J.
    Luznik, Leo
    SEMINARS IN HEMATOLOGY, 2015, 52 (03) : 232 - 242